NeuroVive and to-BBB awarded Eurostars grant for development of stroke therapy

04-Oct-2011 - Sweden

NeuroVive Pharmaceutical AB and to-BBB have been awarded a grant of €1 million through the Eureka Eurostars program for the joint development of therapies for stroke and other acute neurological conditions.

The Eurostars program has awarded NeuroVive Pharmaceutical and to-BBB technologies, a grant of approximately €500,000 each. This grant supports their joint preclinical development program on a potential new treatment for stroke patients. In this program NeuroVive's cyclosporin A for the treatment of neurological damage is combined with to-BBB's G-Technology® to enhance delivery of this drug across the blood-brain barrier. The strategic collaboration between the two companies commenced in October 2010 and the Eurostars grant solidifies and accelerates this partnership.

"NeuroVive's expertise in the area of acute neurological conditions and their leading clinical work with NeuroSTAT® in traumatic brain injuries, provides a strong base for this program." says Pieter Gaillard, CSO of to-BBB, "Since the blood-brain barrier limits drug penetration in stroke patients when they need it most, to-BBB's proprietary G-Technology® holds promise to enhance brain delivery of cyclosporin-based pharmaceuticals for this devastating disorder."

"We are proud that our innovative partnership has been recognized by the Eurostars program. Our project received ranking position 20 out of 348 initiatives in a strong competitive environment. We look forward to accelerate the partnership of NeuroVive and to-BBB with the aim to generate therapies for the large stroke market and other acute neurological conditions", says Mikael Bronnegard, CEO of NeuroVive.

https://www.bionity.com/en/news/134630/neurovive-and-to-bbb-awarded-eurostars-grant-for-development-of-stroke-therapy.html